Effect of Once-weekly Subcutaneous Administration of NNC0487-0111 on Energy Intake, Appetite and Postprandial Metabolism in Participants With Obesity - a Randomised, Placebo-controlled, Double Blinded Study

Registration

Registration

NCT07508020

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE1

Masking

QUADRUPLE

Status

RECRUITING

Enrollment

120

Start

2026-03-30

Primary completion

2028-01-19

Lead sponsor

Novo Nordisk A/S

Conditions

Obesity

Interventions

DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

OTHER:U1111-1319-9246; OTHER:2025-521393-34; NIH:2025

Registered primary outcomes

• Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 126 [From Baseline to Day 126]
• Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 182 [From Baseline to Day 182]
• Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box to Day 238 [From Baseline to Day 238]